Evidence map›Paper›PMID 35630836›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis and Biochemical Evaluation of 8

Jing Wu, Bo Feng, Li-Xin Gao, Chun Zhang, Jia Li, Da-Jun Xiang, Yi Zang, Wen-Long Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Synthesis of Heteroaromatic Compounds.Molecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jing WuSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Bo FengSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Li-Xin GaoSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Chun ZhangSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Jia LiSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Da-Jun XiangXishan People's Hospital of Wuxi City, Wuxi 214105, China.ORCID 0000-0002-3825-0692
Yi ZangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0001-9835-922X
Wen-Long WangSchool of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Jiangnan University · CNShenyang Pharmaceutical University · CNChinese Academy of Sciences · CNWuxi People's Hospital · CN

Funding

Natural Science Foundation of Jiangsu Province BK20190608the science and technology development foundation of Wuxi N2020X016
6 · The paper itself

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 is a global burden on human health and economy. The 3-Chymotrypsin-like cysteine protease (3CL

Indexed as

COVID-19 Drug TreatmentProtease InhibitorsCysteine EndopeptidasesHumansMolecular Docking SimulationPandemicsSARS-CoV-2ThiazolesViral ProteinsCysteine EndopeptidasesProtease InhibitorsThiazolesViral ProteinsCOVID-19drug design and synthesisMpro inhibitorsstructure-activity relationships (SAR)

Identifiers

PMID35630836
PMCPMC9145245
OpenAlexW4281387779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.